

► Press Release

Hospitex Initiates International Dialogues for Pilot Projects in Oncology Diagnostics Following ADB Delegation Visit

Paris, November 24, 2025 – 5:45 pm CET – Hospitex, the fully owned Italian subsidiary of **Aliko Scientific (Ikonisys SA, Euronext Growth Paris: ALIKO)** and leader in the production of cytology medical devices, announces that it is preparing the pilot project of **Urine24** in the Far East, following ADB (Asian Bank Development) Delegation Visit.

The visit took place as part of the **Health Study Tour**, an initiative promoted by the Italian Ministry of Economy and Finance (**MEF**) in collaboration with the Italian Trade Agency (**ICE**) and the Asian Development Bank (ADB). Held in Italy from September 22 to 26, 2025, the program brought together representatives from the **Ministries of Health of Thailand, the Philippines, Uzbekistan, and Tajikistan**, alongside ADB officials.

During the delegation's visit to **Hospitex's headquarters in Sesto Fiorentino**, at the heart of Tuscany's biomedical district, guests were introduced to the company's advanced diagnostic platforms, including **Turnkey Labs** and **Urine24**, a scalable and cost-efficient screening kit for the early detection of urinary tract cancers.

*"Following the company visit, which generated strong interest among institutional stakeholders, we have initiated constructive dialogues with all participating countries to launch the **first pilot projects financed by the Development Bank**. Hospitex's inclusion represents an institutional recognition of our contribution to advancing accessible, technology-driven oncology diagnostics and of our long-term commitment to expanding Made in Italy healthcare innovation across international markets," said **Francesco Trisolini, CEO of Hospitex**.*

*"**Urine24** attracted the greatest interest from the visiting countries, as its "turnkey" and modular design makes it easily implementable in healthcare systems of any size, particularly in developing and emerging markets seeking rapid deployment of diagnostic capacity."*



About ALIKO SCIENTIFIC (Ikonisys SA)

Headquartered in Paris, ALIKO SCIENTIFIC is the parent company of an international ecosystem of businesses dedicated to advancing oncology diagnostics. Listed on Euronext Growth Paris under the ticker ALIKO, the company coordinates industrial, financial and research activities through its subsidiaries: Ikonisys Inc. (USA) and Hospitex International (Italy). ALIKO SCIENTIFIC's mission is to innovate cancer diagnosis by uniting cutting-edge technologies, resources, and strategic investments to create a global center of excellence in oncology.

For more information, visit: www.alikoscientific.com

About IKONISYS

Ikonisys is a global leader in automated diagnostics, specializing in fluorescence in situ hybridization (FISH) and circulating tumor cell (CTC) detection. Leveraging advanced artificial intelligence (AI) and a fully automated microscopy platform, Ikonisys provides unmatched precision, scalability, and efficiency in cancer diagnostics and treatment monitoring. Recognized as pioneer in automation for rare cell detection, Ikonisys is at the forefront of personalized medicine, empowering clinicians to deliver targeted therapies and improve patient outcomes.

For more information, visit: www.ikonisys.com

About HOSPITEX

Hospitex, based in Florence, Italy, is a global leader in cytology innovation. The company conducts in-house research, development, and production, thus ensuring the highest standards of quality. Hospitex offers the world's most advanced Liquid-Based Cytology (LBC) technology, capable of processing any cytological sample with unmatched precision. Hospitex is uniquely positioned as the only company fully prepared for seamless digital integration, paving the way for a transformative future in cytology diagnostics.

For more information, visit: www.hospitex.com

Contacts

Ikonisys	NewCap	NewCap
Alessandro Mauri	Louis-Victor Delouvrier	Arthur Rouillé
CFO	Investor Relations	Media Relations
investors@ikonisys.com	ikonisys@newcap.eu	ikonisys@newcap.eu
	Tel.: +33 (0)1 44 71 94 94	Tel.: +33 (0)1 44 71 00 15

Disclaimer

This press release contains forward-looking statements about the Company's prospects and development. These statements are sometimes identified by the use of the future tense, the conditional tense and forward-looking words such as "believe", "aim to", "expect", "intend", "estimate", "believe", "should", "could", "would" or "will" or, where appropriate, the negative of these terms or any other similar variants or expressions. This information is not historical data and should not be construed as a guarantee that the facts and data set forth will occur. This information is based on data, assumptions and estimates considered reasonable by the Company. It is subject to change or modification due to uncertainties relating to the economic, financial, competitive and regulatory environment. This information contains data relating to the Company's intentions, estimates and objectives concerning, in particular, the market, strategy, growth, results, financial situation and cash flow of the Company. The forward-looking information contained in this press release is made only as of the date of this press release. The Company does not undertake to update any forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and therefore cannot anticipate all of the risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of any one risk or combination of risks could cause results to differ materially from those expressed in any forward-looking information, it being recalled that none of this forward-looking information constitutes a guarantee of actual results.